CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of ...

While the telephone brought comfort, smartphones changed lives. While factories powered economies, artificial intelligence ...

Splitting shares won't double your money. When a stock splits, shareholders each get more shares. The price per share falls proportionally.

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $59.07, moving -3.46% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.1%.

Discover how Simplify Health Care ETF outperforms with active healthcare stock selection, offering alpha where others see ...

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds ...

Cell therapy refers to a treatment that involves the use of living cells to treat diseases. The cell therapy market has been ...

On Sept 17, 2025, Cathie Wood-led Ark Invest executed significant trades involving Bullish, Kratos Defense, Pony AI, and Robinhood. These reflect Ark's focus on emerging tech and defense sectors.

But investors who want to buy the Ark Innovation ETF for 2026 should keep their expectations in check. Targeting a return of 13.9% (in line with its long-term average) in the new year is definitely ...